The transfer of antibiotic residues and antibiotic resistant bacteria into the environment and subsequently into animal drinking water may have an effect on the transmission of resistant bacteria and their resistance genes back into the human population.
This holistic One Health view of antibiotic resistance is at the heart of our project. We want to determine if hospital wide antimicrobial stewardship implementation will reduce antibiotics and antibiotic resistant bacteria from entering the environment and if the reduction of antibiotic concentrations will lower the transfer of resistance genes within and between bacteria in the environment and in animals. We will show that hospital wastewater is a hotspot for selection of resistance and pave the way for future, targeted interventions aimed at reducing the amounts of antibiotics released into the environment even further.
- Adam Roberts, Liverpool School of Tropical Medicine, United Kingdom (Coordinator)
- Andrew Singer, UK Centre for Ecology and Hydrology, United Kingdom
- Nina Langeland, University of Bergen, Norway
- Michael Brouwer, Wageningen Bioveterinary Research, Netherlands
The global spread of antimicrobial resistance (AMR) among pathogenic bacteria is recognized as one of the biggest concerns in public health and a research priority in microbiology.
Drug-resistance increases exponentially for certain bacterial organisms and is becoming the main threat to human health worldwide. As a consequence, national and international authorities have emphasized the need to taking a broad, coordinated approach to develop new antimicrobial strategies to fight against drug-resistant bacteria across multiple sectors such as human health and animal health, agriculture and environment1 (i.e. ‘One health’ major challenge).
The STARS-TAP research program aims at developing an innovative non-antibiotic antibacterial methodology to specifically target AMR strains from natural bacterial communities in several ecosystems in situ. The proposed methodology is based on Targeted-Antibacterial-Plasmids (TAPs) that use DNA conjugation to deliver CRISPR/Cas systems exerting a strain-specific antibacterial activity. If successful, our research would represent a real breakthrough for clinical and environmental microbiology, and open new options for the elimination of AMR strains from various ecosystems. This unexplored and versatile strategy complementary to antibiotic treatments holds the potential to be used for preventive decolonization purposes, or even in agriculture to tackle AMR prevalence in amended soils.
- Christian Lesterlin, Centre National de la Recherche Scientifique, France (Coordinator)
- Pierre Bogaerts, UCL – Université Catholique de Louvain, Belgium
- Gregory Jubelin, French National Research Institute for Agriculture, Food and Environment, France
- Anna Marzec-Grzadziel, Institute of Soil Science and Plant Cultivation – State Research Institute, Poland
- William Couet, French National Institute of Health and Medical Research, France
Antibiotic resistance costs lives and money. Yet if we don’t have a good grasp of the numbers we will never know where it lies in terms of our other national priorities.
In Africa we have especially little evidence on how people, animals, and the environment are affected by it. So those who make decisions do not see it at a particular problem and, as a consequence, those who hold the purse strings in government do not fund the necessary efforts to combat antibiotic resistance.
This project will estimate the full economic burden imposed by antibiotic resistance (epidemiological and financial) in Malawi and Zambia in order to fill this evidence gap. Findings from this work should help enhance political will to take greater action. It will also allow more informed decisions to be made about how best to tackle antibiotic resistance locally by calculating the important cost-related numbers that allow different strategies to be compared. Crucially this project will bring together the key people needed to make real and further progress on this issue each of these two countries. And, if successful, Malawi and Zambia will be setting the example for how to combat antibiotic resistance in other parts of Africa.
- Chantal Morel, University Hospital Bonn, Germany (Coordinator)
- Finola Leonard, University College Dublin, Ireland
- Chisomo Msefula, University of Malawi, College of Medicine, Malawi
- Luigia Scudeller, Azienda Ospedaliero-Universitaria di Bologna, Italy
- Lloyd Matowe, Eden University, Zambia
- Herman Goosens, University of Antwerp, Belgium
Antimicrobial resistance (AMR) links together people, plants, animals and their environments under the One Health umbrella. In this work we will similarly link interventions aimed at AMR by considering their impact not only in terms of impact on hospitals, communities or farmers, but across all of these groups.
This is key to informing optimal intervention selection by governments in tackling AMR in the future. Our research will combine statistical analysis, mathematical simulations and economic-impact models within a single intervention assessment framework. We will bring together an interdisciplinary team of economists, mathematical modellers and veterinary scientists to apply this modelling framework to three country cases studies: England, Senegal and Denmark. All three countries are global leaders in terms of AMR data collection and intervention, providing ideal settings for intervention assessment. Our outcome will be a ranking of farm-level interventions for policymakers to assess their impact from a One Health perspective, and an insight into where more data in the future would be most beneficial, in terms of reducing uncertainty in such economic evaluations of interventions.
- Gwenan Knight, London School of Hygiene and Tropical Medicine, United Kingdom (Coordinator)
- Michel Dione, International Livestock Research Institute, Senegal
- Ana Mateus, Royal Veterinary College, United Kingdom
- Nichola Naylor, Public Health England, United Kingdom
- Dagim Belay, University of Copenhagen, Denmark
The spread of multi-drug resistant (MDR) bacteria in food-producing animals including broilers is a global public health concern.
Controlling growth of MDR bacteria and limiting the transmission of antimicrobial resistance genes in broilers could be an effective mitigation strategy. To counteract the spread of MDR bacteria among zoonotic pathogens in food-producing animals and reduce the risk of their transmission to humans or the environment, antibiotic use in animal husbandry has to be reduced. Bacteriophage therapy is increasingly accepted as an environmentally-friendly antimicrobial intervention strategy, effective at specifically targeting bacterial pathogens, to prevent the transmission of resistant bacteria from foods to humans and vice versa.
We use MDR Salmonella and E. coli in broilers as a model and will first select the most efficient phage combinations to specifically reduce these bacteria and MDR plasmids in broilers. Using laboratory, an experimental chicken gut model and farm-level experiments, we will then establish the efficacy of phage formulations as feed additives within a commercial farming context to reduce bacterial numbers and progressively reduce MDR plasmid carriage in broilers. We will test the effect of phage therapy on intestinal parameters of the treated broilers and also on the broiler intestinal microbiome and resistome composition. We will investigate the transmission of AMR plasmids between different enterobacteria in the broiler gut and improve on-site detection of MDR foodborne pathogens as an early warning system at farm level.
- Ulrich Dobrindt, Universität Münster, Germany (Coordinator)
- Clara Marín-Orenga, Universidad Cardenal Herrera – CEU, Spain
- Muna Anjum, Animal and Plant Health Agency, United Kingdom
- Raul Fernandez Lopez, Universidad de Cantabria, Spain
- Danish Malik, Loughborough University, United Kingdom
- Annamária Szmolka, Veterinary Medical Research Institute, Hungary
- Eliora Ron, Tel Aviv University, Israel
PhageLand is aimed to develop a novel intervention strategy combining the low-cost and eco-friendly capacity of constructed wetlands with the specificity of bacteriophages (i.e., viruses killing bacteria) to prevent the dissemination of antibiotic resistance from wastewater into surface waters.
PhageLand will investigate the prevalence of antibiotic resistant bacterial pathogens (ARB) in low-middle income countries (LMICs) in Eastern Europe, which will be then used as targets for the development of a dedicated phage-based treatment for their specific removal from communal wastes.
In parallel, PhageLand will assess: a) the purification capacity of two reference, full-scale constructed wetlands operating in Spain and Moldova in the removal of antibiotic residues, ARB and antibiotic resistance genes; and b) the potential risk associated with the dissemination of these biological pollutants within indigenous bacterial communities and among animals inhabiting constructed wetlands.
Finally, PhageLand will develop a pilot plant to scale-up the phage-wetland combined technology to assess its performance under real environmental conditions. This proof-of-concept will be used to demonstrate the efficacy of this nature-based technology for the removal of multidrug-resistant pathogens from communal wastes and to encourage stakeholders for its implementation in wastewater treatment to prevent the dissemination of antimicrobial resistance. The PhageLand technology will be particularly useful in LMICs, where costly and power-demanding treatment plants are difficult to set up.
- Carles Borrego, Catalan Institute for Water Research, Spain (Coordinator)
- Lukasz Dziewit, University of Warsaw, Poland
- Malgorzata Grzesiuk-Bieniek, Warsaw University of Life Sciences, Poland
- Rob Lavigne, KU Leuven, Belgium
- Evelien Adriaenssens, Quadram Institute Bioscience, United Kingdom
- David Weissbrodt, Delft University of Technology, Netherlands
- Alina Ferdohleb, Nicolae Testemitanu State University of Medicine and Pharmacy, Moldova
In middle-income countries antibiotic resistance is increasing causing suffering and high mortality. In 12 Vietnamese hospitals half of patients were colonised with “superbugs” called carbapenem resistant Enterobacteriaceae, for short CRE , at admission 13% and after 2 weeks in hospital 89%.
CRE colonization cause hospital infections and high mortality. As many patients are CRE colonized at hospital discharge it can spread to the household members and out in community and environment. If CRE spreads in the community it will be very difficult to treat community infections as urinary tract infections and pneumonia, increasing treatment times, costs and mortality. It is hence important to stop the spread of CRE from hospitals to community.
In our research we will follow patients that are CRE colonised at discharge out to their households. The households will be randomized to intervention and control group. An intervention to improve hygiene and decrease unnecessary antibiotic use will be evaluated on CRE transmission in the household and to domesticated. Colistin, a last resort antibiotic for very ill patients, is often used for animals in feed as growth promoter, selecting for antibiotic resistance that boomerang back into hospitals. We will assess colistin resistance in households and animals and to targeted interventions to reduce transmission. Wastewater from hospitals will be tested for antibiotics and resistant bacteria. To check the relatedness of bacteria in humans, animals and environment resistance genes will be investigated.
- Håkan Hanberger, Linköping University, Sweden (Coordinator)
- Phuc Duc Pham, Hanoi University of Public Health, Vietnam
- Dien Minh Tran, Vietnam National Children’s Hospital/ Research Institute of Childrens Health, Vietnam
- Yaovi Mahuton Gildas Hounmanou, University of Copenhagen, Denmark
- Mattias Larsson, Karolinska Institutet, Sweden
- P Velavan Thirumalaisamy, The Universitätsklinikum Tübingen, Germany
- Flavie Goutard, Centre de coopération internationale en recherche agronomique pour le développement, France
This project addresses the issue of occupational and environmental exposure to livestock-associated MRSA in pig farms.
Using bacterial phages, we will try to reduce the transmission of MRSA from sows to their piglets during the nursing phase. Specific phage cocktails will be designed using several phages to control MRSA on the skin of sows and in their environment. This is done to produce MRSA negative piglets in herds despite having positive sows. A reduction of MRSA in the piglets is expected to contribute to the reduction of MRSA in the whole pig production pyramid. This in turn will reduce the exposure of people working on pig farms and at slaughterhouses to this kind of MRSA. In regions with intensive pig husbandry, livestock associated MRSA may contribute substantially to the overall burden of MRSA in the hospital sector. We aim to reduce this burden.
At the same time we will study potential side effects of the use of phages in pigs on the bacterial community living on pigs, in their environment and in aerosols found in pig stables. We will study changes to this community and will also study the persistence of the bacterial phages in the bacterial community and the environment.
Finally we will model the effect of the use of the phages on the transmission of the resistant bacteria within the herds, between herds and to the public health system.
- Bernd-Alois Tenhagen, German Federal Institute for Risk Assessment, Germany (Coordinator)
- Udo Jäckel, Federal Institute for Occupational Safety and Health, Germany
- Thomas Rosendal, National Veterinary Institute, Sweden, Sweden
- Kyrre Kausrud, Norwegian Veterinary Institute, Norway
- Annemarie Käsbohrer, University of Veterinary Medicine, Austria
Many of the most important one-health AMR genes are carried on mobile genetic elements that move between bacterial strains through the process of conjugation. The genetic mobility of these AMR genes allows them to become widely disseminated across species of bacteria, including harmless commensal strains and dangerous pathogen strains, and ecological niches, including humans, farms and the environment.
In our project, we will develop a series of novel interventions to combat these mobile resistance genes. First, we will develop novel genetic tools that will destroy plasmids carrying resistance genes and selectively kill AMR bacteria. In many regions of the world, infants are commonly colonised with AMR bacteria, complicating the treatment of dangerous infections, such as neonatal sepsis. We will test the ability of our genetic tools to eradicate AMR from the neonatal microbiome using experiments in mice containing a microbiome that is typical of human infants.
Some phage (viruses that infect bacteria) infect and kill bacteria that carry conjugative plasmids. We will test the ability of both phage and novel genetic tools to eliminate AMR from the gut microbiome of chickens. Chickens provide a key source of animal protein (global production is about 120 million tonnes per year), but chickens act as an important source of AMR bacteria that can transfer to humans through food and through the use of chicken manure as a fertiliser.
This two pronged approach will allow us to reduce the transmission of AMR to humans and to eliminate AMR from a high risk human population.
- Craig MacLean, University of Oxford, United Kingdom (Coordinator)
- Michael Brockhurst, University of Manchester, United Kingdom
- Alvaro San Millan, Centro Nacional de Biotecnología, Spain
- Jose Antonio Escudero, Universidad Complutense, Spain
- Bärbel Stecher-Letsch, Max von Pettenkofer-Institute, LMU Munich, Germany
- Didier Mazel, Institut Pasteur, France
- Tao He, Jiangsu Academy of Agricultural Sciences, China
The central aim of MISTAR is to implement and quantify the effect of novel intervention strategies based on the preservation of the “healthy microbiota” to eradicate and control the spread of antimicrobial resistance (AMR).
We will do this using a One Health approach that involves hospitalized patients, healthy humans, pets, farm animals and the environment. In MISTAR we will follow three main approaches to control the spread of AMR. (i) Intervene with the gut microbiota either by prioritizing potential interventions based of microbiota composition indices/diagnostic tools or by using fecal microbiota transplantation (FMT) to modulate the gut microbiota to reduce and possibly avoid the colonization of and further infections by multidrug resistance pathogens. (ii) Intervene with airborne dust-bound spread of antibiotic resistant bacteria (ARB) between pets and humans in households, farm animals and hospitalized patients by applying air purifiers to remove these microorganisms from the air. Finally, we will (iii) develop novel innovative intervention approaches aimed at specifically targeting ARB in complex microbial communities, like the intestinal tract and sewage.
MISTAR will bring perspectives on novel interventions to reduce the emergence of antibiotic resistance that can readily be integrated into existing organisational structures that are also applicable in low-and-middle income countries, and innovative technologies, which needs investment.
- Marcel de Zoete, University Medical Centre Utrecht, Netherlands (Coordinator)
- Teresa M. Coque, Instituto Ramón y Cajal de Investigación Sanitaria, Spain
- Surbhi Malhotra- Kumar, University of Antwerp, Belgium
- Stineke van Houte, University of Exeter, United Kingdom
- Willem van Schaik, University of Birmingham, United Kingdom
- Alex Bossers, Utrecht University, Netherlands
- Ilana Lopes Baratella da Cunha Camargo, University of São Paulo, Brazil